Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2008 1
2010 1
2017 5
2018 2
2019 2
2021 3
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience.
Chiron R, Hoefsloot W, Van Ingen J, Marchandin H, Kremer L, Morisse-Pradier H, Charriot J, Mallet JP, Herrmann JL, Caimmi D, Moreau J, Dumont Y, Godreuil S, Bergeron A, Drevait M, Bouzat-Rossigneux E, Terrail N, Andrejak C, Veziris N, Grenet D, Coudrat A, Catherinot E. Chiron R, et al. Among authors: grenet d. Open Forum Infect Dis. 2022 Sep 11;9(10):ofac465. doi: 10.1093/ofid/ofac465. eCollection 2022 Oct. Open Forum Infect Dis. 2022. PMID: 36267258 Free PMC article.
We also assessed the association of patient drug compliance with culture conversion and clinical outcomes. RESULTS: Twenty-six patients had long-term follow-up data available. Culture conversion was achieved in 54% (14/26) of the patients with no difference between CF and …
We also assessed the association of patient drug compliance with culture conversion and clinical outcomes. RESULTS: Twenty-six patients had …
[Updated indications and contraindications in 2022 for lung transplantation in France].
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Le Guen M, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: grenet d. Rev Mal Respir. 2022 Dec;39(10):855-872. doi: 10.1016/j.rmr.2022.10.005. Epub 2022 Nov 10. Rev Mal Respir. 2022. PMID: 36372607 Review. French.
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and multifaceted attempts have been made to meet the challenges raised by surgical management, perioperative care, and long-term medical com …
Major developments have been impelled over the years by painstaking efforts at LTx centers to improve donor and recipient selection, and mul …
Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.
Martin C, Reynaud-Gaubert M, Hamidfar R, Durieu I, Murris-Espin M, Danner-Boucher I, Chiron R, Leroy S, Douvry B, Grenet D, Mely L, Ramel S, Montcouquiol S, Lemonnier L, Burnet E, Paillasseur JL, Da Silva J, Burgel PR. Martin C, et al. Among authors: grenet d. J Cyst Fibros. 2022 May;21(3):489-496. doi: 10.1016/j.jcf.2022.01.012. Epub 2022 Feb 2. J Cyst Fibros. 2022. PMID: 35123901
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary disease, often leading to suspend the indication for lung transplantation. Yet no long-term data is available in lung transplant can …
BACKGROUND: Elexacaftor-tezacaftor-ivacaftor induces rapid clinical improvement in patients with cystic fibrosis (CF) and advanced pulmonary …
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome.
Danger R, Royer PJ, Reboulleau D, Durand E, Loy J, Tissot A, Lacoste P, Roux A, Reynaud-Gaubert M, Gomez C, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Dahan M, Knoop C, Botturi K, Foureau A, Pison C, Koutsokera A, Nicod LP, Brouard S, Magnan A; COLT and SysCLAD Consortia. Danger R, et al. Front Immunol. 2018 Jan 11;8:1841. doi: 10.3389/fimmu.2017.01841. eCollection 2017. Front Immunol. 2018. PMID: 29375549 Free PMC article.
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term survival after lung transplantation. Identifying predictors of BOS is essential to prevent the progression of dysfunction before irreversible dama …
Bronchiolitis obliterans syndrome (BOS), the main manifestation of chronic lung allograft dysfunction, leads to poor long-term surviv …
2022 Update of indications and contraindications for lung transplantation in France.
Le Pavec J, Pison C, Hirschi S, Bunel V, Mordant P, Brugière O, Guen ML, Olland A, Coiffard B, Renaud-Picard B, Tissot A, Brioude G, Borie R, Crestani B, Deslée G, Stelianides S, Mal H, Schuller A, Falque L, Lorillon G, Tazi A, Burgel PR, Grenet D, De Miranda S, Bergeron A, Launay D, Cottin V, Nunes H, Valeyre D, Uzunhan Y, Prévot G, Sitbon O, Montani D, Savale L, Humbert M, Fadel E, Mercier O, Mornex JF, Dauriat G, Reynaud-Gaubert M. Le Pavec J, et al. Among authors: grenet d. Respir Med Res. 2023 Jun;83:100981. doi: 10.1016/j.resmer.2022.100981. Epub 2022 Nov 28. Respir Med Res. 2023. PMID: 36565563
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient selection, combined with multifaceted efforts to overcome challenges raised by the surgical procedure, perioperative care, and long-term …
The considerable developments have been driven over the years by indefatigable work conducted at LTx centers to improve donor and recipient …
Results of Lung Transplantation for Cystic Fibrosis With Selected Donors Over 65 Years Old.
Glorion M, Sarsam M, Roux A, Stern M, Belousova N, Fessler J, Pricopi C, De Wolf J, Picard C, Brugière O, De Miranda S, Grenet D, Tachon G, Cerf C, Parquin F, Le Guen M, Chapelier A, Vallée A, Sage E. Glorion M, et al. Among authors: grenet d. Transpl Int. 2023 Jun 12;36:11180. doi: 10.3389/ti.2023.11180. eCollection 2023. Transpl Int. 2023. PMID: 37404718 Free PMC article.
The use of lungs from donors over 65 years for cystic fibrosis recipients allows extension of the donor pool without compromising results. Longer follow-up is needed to assess the long-term effects of this practice....
The use of lungs from donors over 65 years for cystic fibrosis recipients allows extension of the donor pool without compromising results. L …
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR, Durieu I, Chiron R, Ramel S, Danner-Boucher I, Prevotat A, Grenet D, Marguet C, Reynaud-Gaubert M, Macey J, Mely L, Fanton A, Quetant S, Lemonnier L, Paillasseur JL, Da Silva J, Martin C; French Cystic Fibrosis Reference Network Study Group. Burgel PR, et al. Among authors: grenet d. Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC. Am J Respir Crit Care Med. 2021. PMID: 33600738

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence interval) in weight was +4.2 kg (+3.9 to +4.6; P < 0.0001). The number of patients requiring long-term oxygen, noninvasive ventil

…

The mean (95% confidence interval) absolute increase in the ppFEV(1) was +15.1 (+13.8 to +16.4; P < 0.0001), and the mean (95% confidence

…
Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung.
Mouraux S, Bernasconi E, Pattaroni C, Koutsokera A, Aubert JD, Claustre J, Pison C, Royer PJ, Magnan A, Kessler R, Benden C, Soccal PM, Marsland BJ, Nicod LP; SysCLAD Consortium. Mouraux S, et al. J Allergy Clin Immunol. 2018 Feb;141(2):718-729.e7. doi: 10.1016/j.jaci.2017.06.022. Epub 2017 Jul 18. J Allergy Clin Immunol. 2018. PMID: 28729000 Free PMC article. Clinical Trial.
BACKGROUND: Homeostatic turnover of the extracellular matrix conditions the structure and function of the healthy lung. In lung transplantation, long-term management remains limited by chronic lung allograft dysfunction, an umbrella term used for a heterogeneous ent …
BACKGROUND: Homeostatic turnover of the extracellular matrix conditions the structure and function of the healthy lung. In lung transplantat …
Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation.
Brosseau C, Danger R, Durand M, Durand E, Foureau A, Lacoste P, Tissot A, Roux A, Reynaud-Gaubert M, Kessler R, Mussot S, Dromer C, Brugière O, Mornex JF, Guillemain R, Claustre J, Magnan A, Brouard S; COLT and SysCLAD Consortia. Brosseau C, et al. Am J Transplant. 2019 Nov;19(11):3162-3175. doi: 10.1111/ajt.15532. Epub 2019 Aug 21. Am J Transplant. 2019. PMID: 31305014 Free article.
Bronchiolitis obliterans syndrome is the main limitation for long-term survival after lung transplantation. Some specific B cell populations are associated with long-term graft acceptance. ...CD9-expressing B cells appear as a contributor to a favorable environment …
Bronchiolitis obliterans syndrome is the main limitation for long-term survival after lung transplantation. Some specific B cell popu …
21 results